Lupin has received a communication from the USFDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between 16 September to 20 September 2019 as Official Action Indicated (OAI).
The inspection at the Tarapur facility had closed with three observations.
The Company does not believe that this inspection classification will hove on impact on disruption of supplies or the existing revenues from operations of this facility.
The Company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)